GlassScriptPhysician profile
Laura G Goldstein
NPI 1295767960
$2,464.40
in general payments reported to CMS, 2019-2025
34 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $80.99 · 2021: $416 · 2022: $392 · 2023: $569 · 2024: $691 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.01 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $352.59 | 2020-2024 | |
| Abbvie INC. | $203.52 | 2021-2025 | |
| Merz Pharmaceuticals, LLC | $178.62 | 2021-2025 | Xeomin, Inbrija |
| Celgene Corporation | $164.54 | 2022-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $155.25 | 2021-2024 | Austedo Xr |
| Tg Therapeutics, INC. | $143.66 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $121.64 | 2021-2023 | Rytary |
| Genentech USA, INC. | $105.98 | 2021-2023 | Ocrevus |
| Eisai INC. | $97.09 | 2023-2025 | |
| Boston Scientific Corporation | $87.85 | 2023-2025 | Vercise |
| Ucb, INC. | $86.12 | 2020-2024 | Fintepla |
| Lilly USA, LLC | $85.96 | 2022-2024 | Kisunla, Reyvow, Emgality |
| Avanir Pharmaceuticals, INC. | $61.25 | 2021-2022 | |
| Amgen INC. | $56.82 | 2021 | |
| Argenx US, INC. | $55.22 | 2024 | Vyvgart Hytrulo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $50.86 | 2021-2023 | Hizentra |
| Pfizer INC. | $49.37 | 2024 | |
| Abbott Laboratories | $43.16 | 2025 | Infinity |
| Octapharma USA, INC. | $34.16 | 2022 | |
| Jazz Pharmaceuticals INC. | $31.08 | 2024 | |
| Alnylam Pharmaceuticals INC. | $29.71 | 2025 | Amvuttra |
| Neurocrine Biosciences, INC. | $27.26 | 2023 | Ingrezza, Ongentys |
| Biohaven Pharmaceutical Holding Company LTD. | $25.71 | 2022 | |
| Janssen Biotech, INC. | $24.85 | 2025 | |
| Acadia Pharmaceuticals INC | $24.35 | 2024 | Nuplazid |
| Acorda Therapeutics, INC | $23.36 | 2021 | |
| Emd Serono, INC. | $21.42 | 2022 | |
| Adamas Pharmaceuticals, INC. | $20.95 | 2021 | |
| Sk Life Science, INC. | $20.17 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.97 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.50 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $15.06 | 2022 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2024 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $14.35 | 2024 | Nuedexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.